GE Gains Sleep Apnea, Anesthesia Products In $860 Mil. Vital Signs Purchase
This article was originally published in The Gray Sheet
Executive Summary
GE Healthcare's $860 million acquisition of Vital Signs Inc. provides an entry into the rapidly growing sleep apnea market and complementary offerings for its anesthesia and broader respiratory care businesses
You may also be interested in...
News Briefs: PillCam Colon Clearance; CGM For Pediatrics; SGR Reform Bill
Given Imaging, soon to be part of Covidien, gained clearance for PillCam Colon capsule endoscopy device. FDA approves its first continuous glucose monitoring system for kids. Congress makes progress in the sustainable growth rate formula bill. More news.
CareFusion Acquires GE Healthcare’s Clinical Consumables Division
Following its acquisition of GE Healthcare’s Vital Signs unit for $500 million, CareFusion will become the second largest player in the more than $3 billion global respiratory and anesthesia consumables market.
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2008
Highlights from the Q3 2008 review of device and diagnostics dealmaking: Led by late-stage rounds, financing for medical device firms--at just over $1bn--showed a slight improvement over the last quarter. IPOs and follow-ons were noticeably absent in Q3, reminiscent of a time in 2003 when the IPO window closed. Not even one of the 13 device M&A transactions reached the billion-dollar mark, but the largest deal, GE Healthcare's buy of Vital Signs for $990mm, came close. In vitro diagnostics/research financings doubled to $643mm led by Illumina's $343mm FOPO. M&A activity in this industry was scant with a mere three transactions. However, Nanogen's reverse merger with Elitech Group--worth $99mm-beat the median M&A deal price ($60mm) over the past five years. Interestingly many in vitro diagnostics players turned to alliances with tech transfer entities in hopes of filling their pipelines.